Is Erasca, Inc. (ERAS) a Buy, Sell, or Hold?
Erasca, Inc.
NASDAQ:ERAS
$19.5 USD
$1.6 (8.94%)
- Volume
- 10.98M
- Average Volume
- 7M
- Market Capitalization
- $6.06B
- P/E Ratio
- -20.97
- Dividend Yield
- 0.00%
- Price Target
- $18.00
- Year High
- $24.28
- Year Low
- $1.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.52
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jonathan E. Lim |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ERAS |
| CUSIP | 29479A108 |
| CIK | 0001761918 |
| Web | https://www.erasca.com |
| Phone | 858 465 6511 |
| Currency | USD |
| Employees | 103 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.12 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.52 |
| Quick Ratio | 9.52 |
| Cash Ratio | 1.77 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.30 |
| Price / Cash Flow | -66.37 |
| Price / Book | 15.08 |
Price Target and Rating
| Average Stock Price Forecast | $18.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | 8.33% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.44 |
| Trailing P/E Ratio | -20.97 |
| PEG Ratio | 0.18 |
| P/E Growth | 0.18 |
| Net Income | $-124.55M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -77.01% |
| Return on Assets | -60.06% |
Financials Score
| AltmanZ Score | 44.62 |
| Piotroski Score | 1.00 |
| Working Capital | 227.12M |
| Total Assets | 461.23M |
| Ebit | -273.77M |
| Market Cap | 5.56B |
| Total Liabilities | 67.71M |
Poll Results
About Erasca, Inc. (NASDAQ:ERAS) Stock
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California. ...
2026-07-14 17:19:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials
2026-07-14 14:33:45
Erasca Inc. (NASDAQ:ERAS) reported updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015, citing encouraging early activity in RAS-mutant solid tumors while outlining plans to advance the candidate into potentially registration-enabling studies.
2026-07-14 12:29:53
New York, New York--(Newsfile Corp. - July 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline. SO WHAT: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
2026-07-14 12:00:00
LOS ANGELES, July 14, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ:ERAS). IF YOU SUFFERED A LOSS ON YOUR ERASCA INVESTMENTS, CLICK HERE BEFORE AUGUST 10, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
2026-07-14 12:00:00
New York, New York--(Newsfile Corp. - July 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Erasca securities between January 14, 2025 and April 26, 2026, both dates inclusive (the "Class Period").
2026-07-14 10:07:00
NEW YORK, July 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Erasca, Inc. (NASDAQ: ERAS). Shareholders who purchased shares of ERAS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
2026-07-14 09:56:00
Important Information Regarding Section 20(a) Individual Liability Claims: Erasca's CEO and CFO Allegedly Certified Misleading Statements About ERAS-0015 While the Company Raised $258.8 Million From Investors Important Information Regarding Section 20(a) Individual Liability Claims: Erasca's CEO and CFO Allegedly Certified Misleading Statements About ERAS-0015 While the Company Raised $258.8 Million From Investors
2026-07-14 09:21:00
Philadelphia, Pennsylvania--(Newsfile Corp. - July 14, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) ("Erasca" or the "Company") on behalf of investors who purchased or acquired Erasca common stock during the period from January 14, 2025 through April 26, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Erasca securities during the Class Period may, no later than August 10, 2026, seek to be appointed as a lead plaintiff representative of the class.
Frequently Asked Questions
-
What is the current Erasca, Inc. (ERAS) stock price?
-
Erasca, Inc.(NASDAQ:ERAS) stock price is $19.5 in the last trading session. During the trading session, ERAS stock reached the peak price of $24.28 while $1.33 was the lowest point it dropped to. The percentage change in ERAS stock occurred in the recent session was 8.94% while the dollar amount for the price change in ERAS stock was $1.6.
-
ERAS's industry and sector of operation?
-
The NASDAQ listed ERAS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ERAS?
-
David Chacko | Chief Financial Officer & Chief Business Officer
Lisa Tesvich-Bonora | Chief People Officer
Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director
Robert Shoemaker | Chief Scientific Officer
Chandra D. Lovejoy | Chief Regulatory Affairs Officer -
How many employees does ERAS have?
-
Number of ERAS employees currently stands at 103. ERAS operates from 10835 Road to the Cure, San Diego, CA 92121, US.
-
Link for ERAS official website?
-
Official Website of ERAS is: https://www.erasca.com
-
How do I contact ERAS?
-
ERAS could be contacted at phone #858 465 6511 and can also be accessed through its website. ERAS operates from 10835 Road to the Cure, San Diego, CA 92121, US.
-
How many shares of ERAS are traded daily?
-
The average number of ERAS shares traded daily for last 3 months was 7M.
-
What is the market cap of ERAS currently?
-
The market value of ERAS currently stands at $6.06B with its latest stock price at $19.5